Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard Rutman

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
The New England Journal of Medicine|June 25, 2010
Ivermectin versus malathion for head liceHoward Rutman
Movement Disorders : Official Journal of the Movement Disorder Society|February 1, 2007
Treatment of essential tremor with the barbiturate T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric acid)Calvin Melmed, Daniel Moros, Howard Rutman
Journal of the American College of Cardiology|August 6, 2021
A Targeted Proteomic Approach Identifies Novel Biomarkers of Arterial Thromboembolic Risk in ENGAGE AF-TIMI 48David D Berg, Robert P Giugliano, Christian T Ruff, et al.
International Journal of Cardiology|February 4, 2018
Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trialIlaria Cavallari, Christian T Ruff, Francesco Nordio, et al.
European Heart Journal|January 10, 2019
Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trialGiuseppe Boriani, Christian T Ruff, Julia F Kuder, et al.
American Heart Journal|February 10, 2016
Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trialAlon Eisen, Robert P Giugliano, Christian T Ruff, et al.
Journal of the American Heart Association|July 13, 2016
Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF-TIMI 48 TrialAlon Eisen, Christian T Ruff, Eugene Braunwald, et al.
European Heart Journal|February 18, 2015
Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†Michelle L O'Donoghue, Christian T Ruff, Robert P Giugliano, et al.
Journal of the American Heart Association|July 2, 2017
Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 TrialAlon Eisen, Christian T Ruff, Eugene Braunwald, et al.
Circulation. Cardiovascular Quality and Outcomes|June 3, 2024
Application of the Win Ratio Method in the ENGAGE AF-TIMI 48 Trial Comparing Edoxaban With Warfarin in Patients With Atrial FibrillationBrian A Bergmark, Jeong-Gun Park, Rose A Hamershock, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
The New England Journal of Medicine|June 25, 2010
Ivermectin versus malathion for head liceHoward Rutman
Movement Disorders : Official Journal of the Movement Disorder Society|February 1, 2007
Treatment of essential tremor with the barbiturate T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric acid)Calvin Melmed, Daniel Moros, Howard Rutman
Journal of the American College of Cardiology|August 6, 2021
A Targeted Proteomic Approach Identifies Novel Biomarkers of Arterial Thromboembolic Risk in ENGAGE AF-TIMI 48David D Berg, Robert P Giugliano, Christian T Ruff, et al.
International Journal of Cardiology|February 4, 2018
Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trialIlaria Cavallari, Christian T Ruff, Francesco Nordio, et al.
European Heart Journal|January 10, 2019
Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trialGiuseppe Boriani, Christian T Ruff, Julia F Kuder, et al.
American Heart Journal|February 10, 2016
Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trialAlon Eisen, Robert P Giugliano, Christian T Ruff, et al.
Journal of the American Heart Association|July 13, 2016
Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF-TIMI 48 TrialAlon Eisen, Christian T Ruff, Eugene Braunwald, et al.
European Heart Journal|February 18, 2015
Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†Michelle L O'Donoghue, Christian T Ruff, Robert P Giugliano, et al.
Journal of the American Heart Association|July 2, 2017
Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 TrialAlon Eisen, Christian T Ruff, Eugene Braunwald, et al.
Circulation. Cardiovascular Quality and Outcomes|June 3, 2024
Application of the Win Ratio Method in the ENGAGE AF-TIMI 48 Trial Comparing Edoxaban With Warfarin in Patients With Atrial FibrillationBrian A Bergmark, Jeong-Gun Park, Rose A Hamershock, et al.
Pageof 2